Abatacept for Patients With COVID-19 and Respiratory Distress

• Status: Withdrawn
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-arm open label trial for hospitalized patients with COVID-19 (Coronavirus). The primary endpoint of the study is to assess the requirement for mechanical ventilation in patients who are admitted to the hospital with COVID-19 infection and a Pulse Oxygen LevelPhase: Phase 1/Phase 2

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborators: Boston Children's Hospital; Boston Children’s Hospital; Brigham and Women's Hospital; Bristol-Myers Squibb
• Treatments: Abatacept

Criteria

Inclusion Criteria:

• Must be at least 18 years old.

• Confirmed SARS-CoV-2 infection, confirmed by polymerase chain reaction (PCR)prior to enrollment

• Evidence of respiratory distress including SpO2
• Radiographic evidence of pulmonary infiltrates.

• Ability to understand and the willingness to provide informed consent.

Exclusion Criteria:

• Patients already intubated/mechanically ventilated at screening will not be eligible.

• Patients with uncontrolled severe bacterial or fungal infections at the time of enrollment.

• Patients with previously diagnosed autoimmune disorders or who were on immunosuppressive medications prior to developing COVID-19 are not eligible

• Pregnant or breastfeeding